Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Mysimba
Mysimba 8 mg/90 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-130320 · Präparat HOS-096899
Co-administration of bupropion with drugs that are metabolised by CYP2D6 isozyme including
certain antidepressants (SSRIs and many tricyclic antidepressants, e.g. desipramine, imipramine,
paroxetine), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g.,
metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide), should be approached
with caution and should be initiated at the lower end of the dose range of the concomitant medicinal
product. Although citalopram is not primarily metabolised by CYP2D6, in one study, bupropion
increased the Cmax and AUC of citalopram by 30% and 40%, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) citalopram (HOS-087802) propafenone (HOS-084530) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) thioridazine (HOS-086281) haloperidol (HOS-085602) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T14:58:00Z · SHA-256 8d91203fd1313606105ccfcfeb588970833594eb1edb4edb571e8c8ed61c515c · Passage cd65a9952c510c78425f288878ffbcc66bc9158597a50f714a7a9b26d908a649 · Zeichen 1889–2538 im Abschnitt
Wechselwirkungen · Cerdelga
Cerdelga 21 mg hard capsules Cerdelga 84 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-130409 · Präparat HOS-096915
CYP2D6 inhibitors in IMs and EMs
After repeated 84 mg twice daily doses of eliglustat in non-PMs, concomitant administration with
repeated 30 mg once daily doses of paroxetine, a strong inhibitor of CYP2D6, resulted in a 7.3- and
8.9-fold increase in eliglustat Cmax and AUC0-12, respectively. Once a day dosing of eliglustat for EMs
and IMs is recommended when a strong CYP2D6 inhibitor (e.g. paroxetine, fluoxetine, quinidine,
bupropion) is used concomitantly in IMs and EMs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) bupropion (HOS-086329) quinidine (HOS-085593) fluoxetine (HOS-085946) eliglustat (HOS-130401)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T15:21:00Z · SHA-256 1c727ba97e10c9a78b07345b037b7efc3b42bce5b1ed72eaf8881cd34d7be69a · Passage 70a592653987ae2c4dbf2faab054fd8b11a06ec377b706529af1bdbe10904e20 · Zeichen 1079–1556 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 300 mg/0.5 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-130696 · Präparat HOS-096947
There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and
other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline,
fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) citalopram (HOS-087802) duloxetine (HOS-089666) venlafaxine (HOS-086573) serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946) fluvoxamine (HOS-085908) escitalopram (HOS-129417)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 7496998149251e36b5a5979e551a8455c10917990713c719e5f50b629ca93bb4 · Zeichen 3396–3695 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 235 mg/0.25 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 21
HOS-130738 · Präparat HOS-096947
There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and
other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline,
fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) citalopram (HOS-087802) duloxetine (HOS-089666) venlafaxine (HOS-086573) serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946) fluvoxamine (HOS-085908) escitalopram (HOS-129417)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 7496998149251e36b5a5979e551a8455c10917990713c719e5f50b629ca93bb4 · Zeichen 3426–3725 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 235 mg/0.25 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 39
HOS-130781 · Präparat HOS-096947
There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and
other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline,
fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) citalopram (HOS-087802) duloxetine (HOS-089666) venlafaxine (HOS-086573) serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946) fluvoxamine (HOS-085908) escitalopram (HOS-129417)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 7496998149251e36b5a5979e551a8455c10917990713c719e5f50b629ca93bb4 · Zeichen 3427–3726 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 300 mg/0.5 mg oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 56
HOS-130817 · Präparat HOS-096947
There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and
other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline,
fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) citalopram (HOS-087802) duloxetine (HOS-089666) venlafaxine (HOS-086573) serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946) fluvoxamine (HOS-085908) escitalopram (HOS-129417)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 7496998149251e36b5a5979e551a8455c10917990713c719e5f50b629ca93bb4 · Zeichen 3389–3688 im Abschnitt
Wechselwirkungen · Rxulti
RXULTI 0.25 mg film-coated tablets RXULTI 0.5 mg film-coated tablets RXULTI 1 mg film-coated tablets RXULTI 2 mg film-coated tablets RXULTI 3 mg film-coated tablets RXULTI 4 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-132037 · Präparat HOS-097184
CYP2D6 inhibitors
Co-administration of a 2 mg single oral dose of brexpiprazole with quinidine (324 mg/day for 7 days),
a potent inhibitor of CYP2D6, increased the AUC of brexpiprazole by 94 % and did not change the
Cmax. Based on results of interaction studies, dose adjustment of brexpiprazole to half the dose is
recommended when administered concomitantly with strong CYP2D6 inhibitors (quinidine,
paroxetine, and fluoxetine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) quinidine (HOS-085593) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-12T14:38:00Z · SHA-256 d060cc667cc18af4e73efacd249c6f69ccb808c8be005b26cc608ba465837472 · Passage e861184c94e1381c1c4e5a58c9679f2ec8c5384f9c4a4ad99e6011c20171f965 · Zeichen 1255–1685 im Abschnitt
Wechselwirkungen · Aripiprazole Zentiva
Aripiprazole Zentiva 5 mg tablets Aripiprazole Zentiva 10 mg tablets Aripiprazole Zentiva 15 mg tablets Aripiprazole Zentiva 30 mg tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-221325 · Präparat HOS-216832
Quinidine and other CYP2D6 inhibitors
In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole
AUC by 107%, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active
metabolite, decreased by 32% and 47%, respectively. Aripiprazole dose should be reduced
to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with
quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may
be expected to have similar effects and similar dose reductions should therefore be applied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) quinidine (HOS-085593) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-08T14:25:00Z · SHA-256 19a0fd8397c8d49ac81f1d35fd7856a088b9bc1c9cd3328f6a1d69ac1b5721ee · Passage e3eb6323c6b5e89bcca03cfef6281a905ceba3ffa7f349a522f51421dd4a7d01 · Zeichen 992–1601 im Abschnitt
Wechselwirkungen · Fintepla
Fintepla 2.2 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 9
HOS-132972 · Präparat HOS-097342
Coadministration of a single 0.35 mg/kg dose of fenfluramine with paroxetine (a strong CYP2D6
inhibitor) at steady state (30 mg once daily) in healthy volunteers increased the AUC 0-t of
fenfluramine by a ratio of 1.8-fold and the C max by a ratio of 1.1-fold, and decreased the AUC 0-t of
norfenfluramine by a ratio of 1.2-fold and the C max by a ratio of 1.3-fold, as compared to fenfluramine
administered alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-09T15:00:00Z · SHA-256 e175f94af1e49d4a11fbbc3e861df1256bc1a0a5d612baaf0706babc5f1fc781 · Passage 363aaff445a8b2c954d16a9299774bc2ae40cebbe2bc3291e8e5f0211f47f18e · Zeichen 2930–3344 im Abschnitt
Wechselwirkungen · Aripiprazole Sandoz
Aripiprazole Sandoz 5 mg tablets Aripiprazole Sandoz 10 mg tablets Aripiprazole Sandoz 15 mg tablets Aripiprazole Sandoz 20 mg tablets Aripiprazole Sandoz 30 mg tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-133646 · Präparat HOS-097480
Quinidine and other CYP2D6 inhibitors
In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC
by 107%, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active metabolite,
decreased by 32% and 47%, respectively. Aripiprazole dose should be reduced to approximately one-half of
its prescribed dose when concomitant administration of aripiprazole with quinidine occurs. Other strong
inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar
dose reductions should therefore be applied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) quinidine (HOS-085593) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-21T11:00:00Z · SHA-256 327ef54b8c9603e9d2d852929d852cc6b552a07adfbdb4be62ec8d86171c0375 · Passage 3710b4910f9b9b5e88c7dc04d1064b5090cc7500e07fa3cb4fd3a98e459169b4 · Zeichen 909–1518 im Abschnitt
Wechselwirkungen · Aripiprazole Accord
Aripiprazole Accord 5 mg tablets Aripiprazole Accord 10 mg tablets Aripiprazole Accord 15 mg tablets Aripiprazole Accord 30 mg tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-222810 · Präparat HOS-217094
Quinidine and other CYP2D6 inhibitors
In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole
AUC by 107 %, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active
metabolite, decreased by 32 % and 47 %, respectively. Aripiprazole dose should be reduced to
approximately one-half of its prescribed dose when concomitant administration of aripiprazole with
quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be
expected to have similar effects and similar dose reductions should therefore be applied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) quinidine (HOS-085593) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-26T17:39:00Z · SHA-256 ab8ef4f2dea1b8b21328e179f0c8775ac95a820a221cb20a26c26f9d4e53e1d7 · Passage 8dba665ffe6b64b523eb56cf6509b40990baa24dc052ded305a55b9ba925f661 · Zeichen 964–1576 im Abschnitt
Wechselwirkungen · Trevicta (previously Paliperidone Janssen)
TREVICTA 175 mg prolonged release suspension for injection TREVICTA 263 mg prolonged release suspension for injection TREVICTA 350 mg prolonged release suspension for injection TREVICTA 525 mg prolonged release suspension for injection · Abschnitt 4.5 · PDF-Seite 10
HOS-223556 · Präparat HOS-217190
In vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone
metabolism, but there are no indications in vitro nor in vivo that these isozymes play a significant role
in the metabolism of paliperidone. Concomitant administration of oral paliperidone with paroxetine, a
potent CYP2D6 inhibitor, showed no clinically significant effect on the pharmacokinetics of
paliperidone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-22T17:58:00Z · SHA-256 99ebe823a4176eaf71ac968669b40cc1d436d37ca85db0659155fedcb56c8f2c · Passage 5f19334ebaad09140f1c66a2b615e61453a9d93ce5e819c767c768105968e022 · Zeichen 2054–2458 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-134494 · Präparat HOS-097580
14
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
ANTIDEPRESSANTS
Paroxetine paroxetine AUC ↓ 39% If antidepressants are co-
20 mg once daily paroxetine Cmin ↓ 37% administered with darunavir with
paroxetine Cmax ↓ 36% low dose ritonavir, the
recommended approach is a dose
#
darunavir AUC ↔
titration of the antidepressant based
#
darunavir Cmin ↔
on a clinical assessment of
#
darunavir Cmax ↔
antidepressant response. In addition,
Sertraline sertraline AUC ↓ 49% patients on a stable dose of these
50 mg once daily sertraline Cmin ↓ 49% antidepressants who start treatment
sertraline Cmax ↓ 44% with darunavir with low dose
#
darunavir AUC ↔ ritonavir should be monitored for
#
darunavir Cmin ↓ 6% antidepressant response.
#
darunavir Cmax ↔
Clinical monitoring is
recommended when co-
Concomitant use of darunavir co- administering darunavir with low
administered with low dose ritonavir dose ritonavir with these
and these antidepressants may increase antidepressants and a dose
concentrations of the antidepressant. adjustment of the antidepressant
(CYP2D6 and/or CYP3A inhibition) may be needed.
Amitriptyline
Desipramine
Imipramine
Nortriptyline
Trazodone
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted darunavir is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with darunavir co-
(induction of CYP450 enzymes) administered with low dose
ritonavir unless an assessment of
the benefit/risk ratio justifies the use
of voriconazole.
Fluconazole Not studied. Darunavir may increase Caution is warranted and clinical
Isavuconazole antifungal plasma concentrations and monitoring is recommended. When
Itraconazole posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole, or fluconazole may daily dose of itraconazole should
increase darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) sertraline (HOS-086247) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 0e227ba8a8f0b79d0adea0b25305dcec4671959e568e634634a5edd206310734 · Zeichen 29798–33588 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56–57
HOS-134618 · Präparat HOS-097580
56
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
ANTIDEPRESSANTS
Paroxetine paroxetine AUC ↓ 39% If antidepressants are co-
20 mg once daily paroxetine Cmin ↓ 37% administered with boosted darunavir,
paroxetine Cmax ↓ 36% the recommended approach is a dose
titration of the antidepressant based
#
darunavir AUC ↔
on a clinical assessment of
#
darunavir Cmin ↔
antidepressant response. In addition,
#
darunavir Cmax ↔
patients on a stable dose of these
antidepressants who start treatment
with boosted darunavir should be
monitored for antidepressant
response.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage e2e88594b4048fd117d7ecc648cd1dae09548aa545e916749e52c9863e79667c · Zeichen 35716–37013 im Abschnitt
Wechselwirkungen · Palonosetron Accord
Palonosetron Accord 250 micrograms solution for injection · Abschnitt 4.5 · PDF-Seite 4
HOS-135561 · Präparat HOS-097730
In a population pharmacokinetic analysis, it has been shown that there was no significant effect on
palonosetron clearance when co-administered with CYP2D6 inducers (dexamethasone and rifampicin) and
inhibitors (including amiodarone, celecoxib, chlorpromazine, cimetidine, doxorubicin, fluoxetine,
haloperidol, paroxetine, quinidine, ranitidine, ritonavir, sertraline or terbinafine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) celecoxib (HOS-113199) cimetidine (HOS-085835) terbinafine (HOS-113069) quinidine (HOS-085593) chlorpromazine (HOS-087796) dexamethasone (HOS-084535) sertraline (HOS-086247) fluoxetine (HOS-085946) ranitidine (HOS-085660) haloperidol (HOS-085602) ritonavir (HOS-084521) amiodarone (HOS-085596) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-20T11:10:00Z · SHA-256 2404468d027dfe60f8107c0349ddcf4fe941a3afb092543c2026d50144230a9d · Passage 63800627ff1679bd1143b6beb92ff852116b69b5b6e7800e524dcb82d6833940 · Zeichen 711–1095 im Abschnitt
Wechselwirkungen · Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan
Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan 600 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 25–26
HOS-225173 · Präparat HOS-217408
25
Effects on medicinal product
levels
Recommendation concerning co-
administration with
Mean percent change in AUC,
Medicinal product by therapeutic efavirenz/emtricitabine/tenofovir
Cmax, Cmin with 90%
areas disoproxil (efavirenz 600 mg,
confidence intervals if
emtricitabine 200 mg, tenofovir
available
disoproxil 245 mg)
(mechanism)
Selective serotonin reuptake inhibitors (SSRIs)
Sertraline/Efavirenz Sertraline: When co-administered with
(50 mg q.d./600 mg q.d.) AUC: ↓ 39% (↓ 27 to ↓ 50) efavirenz/emtricitabine/tenofovir
Cmax: ↓ 29% (↓ 15 to ↓ 40) disoproxil, sertraline dose increases
Cmin: ↓ 46% (↓ 31 to ↓ 58) should be guided by clinical
Efavirenz: response.
AUC: ↔
Cmax: ↑ 11% (↑ 6 to ↑ 16)
Cmin: ↔
(CYP3A4 induction)
Sertraline/Emtricitabine Interaction not studied.
Sertraline/Tenofovir disoproxil Interaction not studied.
Paroxetine/Efavirenz Paroxetine: Efavirenz/emtricitabine/tenofovir
(20 mg q.d./600 mg q.d.) AUC: ↔ disoproxil and paroxetine can be co-
Cmax: ↔ administered without dose
Cmin: ↔ adjustment.
Efavirenz:
AUC: ↔
Cmax: ↔
Cmin: ↔
Paroxetine/Emtricitabine Interaction not studied.
Paroxetine/Tenofovir disoproxil Interaction not studied.
Fluoxetine/Efavirenz Interaction not studied. Since Efavirenz/emtricitabine/tenofovir
fluoxetine shares a similar disoproxil and fluoxetine can be co-
metabolic profile with administered without dose
paroxetine, i.e. a strong CYP2D6 adjustment.
inhibitory effect, a similar lack
of interaction would be expected
for fluoxetine.
Fluoxetine/Emtricitabine Interaction not studied.
Fluoxetine/Tenofovir disoproxil Interaction not studied.
Norepinephrine and dopamine reuptake inhibitor
Bupropion/Efavirenz Bupropion: Increases in bupropion dose should
[150 mg single dose (sustained AUC: ↓ 55% (↓ 48 to ↓ 62) be guided by clinical response, but
release)/600 mg q.d.] Cmax: ↓ 34% (↓ 21 to ↓ 47) the maximum recommended dose of
Hydroxybupropion: bupropion should not be exceeded.
AUC: ↔ No dose adjustment is necessary for
Cmax: ↑ 50% (↑ 20 to ↑ 80) efavirenz.
(CYP2B6 induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) paroxetine (HOS-086246) norepinephrine (HOS-090547) bupropion (HOS-086329) dopamine (HOS-085948) tenofovir disoproxil (HOS-108843) serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-12T16:00:00Z · SHA-256 5d5465edd3c9d217b9da8953c1c65124721547ecce9c7a712313126d1f9412ff · Passage 2de5b55b6eb1006cd20ef31631e5efaa72809f0fe592dc9fb7ad6c44aaf25f35 · Zeichen 63534–67637 im Abschnitt
Wechselwirkungen · Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva 600 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 26–27
HOS-225439 · Präparat HOS-217440
26
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with
Cmax, Cmin with 90% Efavirenz/Emtricitabine/Tenofo
confidence intervals if vir disoproxil Zentiva (efavirenz
available (mechanism) 600 mg, emtricitabine 200 mg,
tenofovir disoproxil 245 mg)
Vigabatrin/efavirenz Interaction not studied. Efavirenz/Emtricitabine/Tenofovi
Gabapentin/efavirenz Clinically significant r disoproxil Zentiva and
interactions are not expected vigabatrin or gabapentin can be
since vigabatrin and gabapentin co-administered without dose
are exclusively eliminated adjustment.
unchanged in the urine and are
unlikely to compete for the same
metabolic enzymes and
elimination pathways as
efavirenz.
Vigabatrin/emtricitabine Interaction not studied.
Gabapentin/emtricitabine
Vigabatrin/tenofovir Interaction not studied.
disoproxil
Gabapentin/tenofovir
disoproxil
ANTICOAGULANTS
Warfarin/efavirenz Interaction not studied. Plasma Dose adjustment of warfarin or
Acenocoumarol/efavirenz concentrations and effects of acenocoumarol may be required
warfarin or acenocoumarol are when co-administered with
potentially increased or Efavirenz/Emtricitabine/Tenofovi
decreased by efavirenz. r disoproxil Zentiva.
ANTIDEPRESSANTS
Selective Serotonin Reuptake Inhibitors (SSRIs)
Sertraline/efavirenz Sertraline: When co-administered with
(50 mg q.d./600 mg q.d.) AUC: ↓ 39% (↓ 27 to ↓ 50) Efavirenz/Emtricitabine/Tenofovi
Cmax: ↓ 29% (↓ 15 to ↓ 40) r disoproxil Zentiva, sertraline
Cmin: ↓ 46% (↓ 31 to ↓ 58) dose increases should be guided
by clinical response.
Efavirenz:
AUC: ↔
Cmax: ↑ 11% (↑ 6 to ↑ 16)
Cmin: ↔
(CYP3A4 induction)
Sertraline/emtricitabine Interaction not studied.
Sertraline/tenofovir Interaction not studied.
disoproxil
Paroxetine/efavirenz Paroxetine: Efavirenz/Emtricitabine/Tenofovi
(20 mg q.d./600 mg q.d.) AUC: ↔ r disoproxil Zentiva and
Cmax: ↔ paroxetine can be co-administered
Cmin: ↔ without dose adjustment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) paroxetine (HOS-086246) vigabatrin (HOS-115599) tenofovir disoproxil (HOS-108843) gabapentin (HOS-090745) serotonin (HOS-085477) sertraline (HOS-086247) acenocoumarol (HOS-109456) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-18T14:27:00Z · SHA-256 c270a1cdb7da090e33611100f559dae18fdf880f595613a4f2237902fa4e3508 · Passage 602b297d333ae586504fa29d006dfb57d5fdaa79eed37e9fd37ee97ea7a91b22 · Zeichen 56030–59120 im Abschnitt
Wechselwirkungen · Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva 600 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 27
HOS-225440 · Präparat HOS-217440
Efavirenz:
AUC: ↔
Cmax: ↔
Cmin: ↔
Paroxetine/emtricitabine Interaction not studied.
Paroxetine/tenofovir Interaction not studied.
disoproxil
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) paroxetine (HOS-086246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-18T14:27:00Z · SHA-256 c270a1cdb7da090e33611100f559dae18fdf880f595613a4f2237902fa4e3508 · Passage e0424d327641b00ae2137db0ea97dfa6e228cf16f926182d24d3fbdd1e8b3110 · Zeichen 59149–59378 im Abschnitt
Wechselwirkungen · Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva 600 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 27–28
HOS-225441 · Präparat HOS-217440
27
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with
Cmax, Cmin with 90% Efavirenz/Emtricitabine/Tenofo
confidence intervals if vir disoproxil Zentiva (efavirenz
available (mechanism) 600 mg, emtricitabine 200 mg,
tenofovir disoproxil 245 mg)
Fluoxetine/efavirenz Interaction not studied. Since Efavirenz/Emtricitabine/Tenofovi
fluoxetine shares a similar r disoproxil Zentiva and
metabolic profile with fluoxetine can be co-administered
paroxetine, i.e. a strong without dose adjustment.
CYP2D6 inhibitory effect, a
similar lack of interaction would
be expected for fluoxetine.
Fluoxetine/emtricitabine Interaction not studied.
Fluoxetine/tenofovir Interaction not studied.
disoproxil
Norepinephrine and dopamine reuptake inhibitor
Bupropion/efavirenz Bupropion: Increases in bupropion dosage
[150 mg single dose AUC: ↓ 55% (↓ 48 to ↓ 62) should be guided by clinical
(sustained release)/600 mg Cmax: ↓ 34% (↓ 21 to ↓ 47) response, but the maximum
q.d.] recommended dose of bupropion
Hydroxybupropion: should not be exceeded. No dose
AUC: ↔ adjustment is necessary for
Cmax: ↑ 50% (↑ 20 to ↑ 80) efavirenz.
(CYP2B6 induction)
Bupropion/emtricitabine Interaction not studied.
Bupropion/tenofovir Interaction not studied.
disoproxil
CARDIOVASCULAR AGENTS
Calcium Channel Blockers
Diltiazem/efavirenz Diltiazem: Dose adjustments of diltiazem
(240 mg q.d./600 mg q.d.) AUC: ↓ 69% (↓ 55 to ↓ 79) when co-administered with
Cmax: ↓ 60% (↓ 50 to ↓ 68) Efavirenz/Emtricitabine/Tenofovi
Cmin: ↓ 63% (↓ 44 to ↓ 75) r disoproxil Zentiva should be
guided by clinical response (refer
Desacetyl diltiazem: to the Summary of Product
AUC: ↓ 75% (↓ 59 to ↓ 84) Characteristics for diltiazem).
Cmax: ↓ 64% (↓ 57 to ↓ 69)
Cmin: ↓ 62% (↓ 44 to ↓ 75)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) paroxetine (HOS-086246) diltiazem (HOS-086288) norepinephrine (HOS-090547) bupropion (HOS-086329) dopamine (HOS-085948) tenofovir disoproxil (HOS-108843) calcium (HOS-085615) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-18T14:27:00Z · SHA-256 c270a1cdb7da090e33611100f559dae18fdf880f595613a4f2237902fa4e3508 · Passage 18f0653261a9051cdf2d5da6897a3cb8535bb764443b3f6158dfa8ca72ae8e0b · Zeichen 59427–62280 im Abschnitt
Wechselwirkungen · Darunavir Krka
Darunavir Krka 400 mg film-coated tablets Darunavir Krka 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-225712 · Präparat HOS-217490
14
Concomitant administration of
Ticagrelor Based on theoretical considerations, boosted darunavir with ticagrelor is
co-administration of boosted darunavir contraindicated (see section 4.3).
with ticagrelor may increase
concentrations of ticagrelor (CYP3A
and/or P-glycoprotein inhibition).
Co-administration of clopidogrel
Clopidogrel Not studied. Co-administration of with boosted darunavir is not
clopidogrel with boosted darunavir is recommended. Use of other
expected to decrease clopidogrel active antiplatelets not affected by CYP
metabolite plasma concentration, which inhibition or induction (e.g.
may reduce the antiplatelet activity of prasugrel) is recommended.
clopidogrel
Warfarin Not studied. Warfarin concentrations may It is recommended that the
be affected when co-administered with international normalised ratio (INR)
boosted darunavir. be monitored when warfarin is
combined with boosted darunavir.
ANTICONVULSANTS
Phenobarbital Not studied. Phenobarbital and phenytoin Darunavir co-administered with low
Phenytoin are expected to decrease plasma dose ritonavir should not be used in
concentrations of darunavir and its combination with these medicines.
pharmacoenhancer. The use of these medicines with
(induction of CYP450 enzymes) darunavir/cobicistat is
contraindicated (see section 4.3).
Carbamazepine carbamazepine AUC ↑ 45% No dose adjustment for darunavir
200 mg twice daily carbamazepine Cmin ↑ 54% /ritonavir is recommended. If there is
carbamazepine Cmax ↑ 43% a need to combine
darunavir AUC ↔ darunavir/ritonavir and
darunavir Cmin ↓ 15% carbamazepine, patients should be
darunavir Cmax ↔ monitored for potential
carbamazepine-related adverse
events. Carbamazepine
concentrations should be monitored
and its dose should be titrated for
adequate response. Based upon the
findings, the carbamazepine dose
may need to be reduced by 25% to
50% in the presence of
darunavir/ritonavir.
The use of carbamazepine with
darunavir co-administered with
cobicistat is contraindicated (see
section 4.3).
Clonazepam Not studied. Co-administration of boosted Clinical monitoring is recommended
darunavir with clonazepam may increase when co-administering boosted
concentrations of clonazepam. (CYP3A darunavir with clonazepam.
inhibition)
ANTIDEPRESSANTS
Paroxetine paroxetine AUC ↓ 39% If antidepressants are co-
20 mg once daily paroxetine Cmin ↓ 37% administered with boosted darunavir,
paroxetine Cmax ↓ 36% the recommended approach is a dose
#
darunavir AUC ↔ titration of the antidepressant based
#
darunavir Cmin ↔ on a clinical assessment of
#
darunavir Cmax ↔ antidepressant response. In addition,
Sertraline sertraline AUC ↓ 49% patients on a stable dose of these
50 mg once daily sertraline Cmin ↓ 49% antidepressants who start treatment
sertraline Cmax ↓ 44% with boosted darunavir should be
#
darunavir AUC ↔ monitored for antidepressant
#
darunavir Cmin ↓ 6% response.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) paroxetine (HOS-086246) phenobarbital (HOS-085617) carbamazepine (HOS-085618) cobicistat (HOS-088111) clonazepam (HOS-116372) clopidogrel (HOS-087927) sertraline (HOS-086247) prasugrel (HOS-112066) ritonavir (HOS-084521) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-28T02:00:00Z · SHA-256 42a250050090ba77cfec6bb0ff0fc9dbbb4e1a422df7d45e8efc6fc459616a05 · Passage 6db36d31af82fcb7a33454414138d2238b726661fd7be10337d56ac171a869cf · Zeichen 30002–35288 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.